Pure MHC Overview

  • Founded
  • 2003
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • 2ndary - Private

Pure MHC General Information

Description

Developer of a biotechnology platform intended to create a novel class of therapeutics for the treatment of cancer and infectious disease. The company's platform specializes in disease-specific target identification, and validation as well as immunotherapeutic drug development for cancer, infectious, and autoimmune diseases and allergy, enabling healthcare practitioners to avail breakthrough therapeutic target discovery and validation with further drug development applications.

Contact Information

Website
www.puremhc.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 7500 Rialto Boulevard, Building 2
  • Suite 260
  • Austin, TX 78735
  • United States
+1 (512) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pure MHC Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 01-Apr-2021 000 Completed Generating Revenue
1. Later Stage VC 18-Jun-2008 000 000 Completed Generating Revenue
To view Pure MHC’s complete valuation and funding history, request access »

Pure MHC Patents

Pure MHC Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2262834-A4 Antibodies as t cell receptor mimics, methods of production and uses thereof Withdrawn 27-Feb-2008 00000000000 0
EP-2262834-A2 Antibodies as t cell receptor mimics, methods of production and uses thereof Withdrawn 27-Feb-2008 00000000000 0
CA-2656583-A1 Antibodies as t cell receptor mimics, methods of production and uses thereof Abandoned 01-Jun-2006 000000000
AU-2007254859-A1 Antibodies as t cell receptor mimics, methods of production and uses thereof Abandoned 01-Jun-2006 000000000
EP-2026837-A2 Antibodies as t cell receptor mimics, methods of production and uses thereof Withdrawn 01-Jun-2006 C07K16/18 0
To view Pure MHC’s complete patent history, request access »

Pure MHC Executive Team (6)

Name Title Board Seat Contact Info
William Hildebrand Ph.D Co-Founder & Chief Scientist of Target Discovery
Thomas Harlan Chief Executive Officer
Steven Mayer MD Chief Medical Officer
You’re viewing 3 of 6 executive team members. Get the full list »

Pure MHC Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial